Tags: Biogen


Does Verubecestat Signal the End of the Amyloid Hypothesis?

Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.


What Does the Failure of Solanezumab Mean?

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.


ADDF-Funded PET Imaging Makes Clinical Trial Success Possible

A treatment has reduced beta-amyloid plaques in the brains of patients with Alzheimer’s disease.